SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

NCT06278857 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER_GOV

Sponsor class

Conditions

Endometrial Cancer Stage I
Mmr Deficiency
Endometrioid Endometrial Adenocarcinoma
Immune-related Adverse Event

Interventions

DRUG: Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI]

Sponsor

Queensland Centre for Gynaecological Cancer

Collaborators

[object Object]